IL160142A0 - Methods and compounds for the targeting of protein to exosomes - Google Patents

Methods and compounds for the targeting of protein to exosomes

Info

Publication number
IL160142A0
IL160142A0 IL16014202A IL16014202A IL160142A0 IL 160142 A0 IL160142 A0 IL 160142A0 IL 16014202 A IL16014202 A IL 16014202A IL 16014202 A IL16014202 A IL 16014202A IL 160142 A0 IL160142 A0 IL 160142A0
Authority
IL
Israel
Prior art keywords
methods
relates
membrane vesicles
well
exosomes
Prior art date
Application number
IL16014202A
Other languages
English (en)
Original Assignee
Anosys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anosys Inc filed Critical Anosys Inc
Publication of IL160142A0 publication Critical patent/IL160142A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16014202A 2001-08-17 2002-08-14 Methods and compounds for the targeting of protein to exosomes IL160142A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31315901P 2001-08-17 2001-08-17
US34399101P 2001-12-26 2001-12-26
PCT/EP2002/009108 WO2003016522A2 (en) 2001-08-17 2002-08-14 Methods and compounds for the targeting of protein to exosomes

Publications (1)

Publication Number Publication Date
IL160142A0 true IL160142A0 (en) 2004-06-20

Family

ID=26978714

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16014202A IL160142A0 (en) 2001-08-17 2002-08-14 Methods and compounds for the targeting of protein to exosomes

Country Status (10)

Country Link
US (1) US7704964B2 (xx)
EP (1) EP1417229B1 (xx)
JP (1) JP4662708B2 (xx)
CN (1) CN100590131C (xx)
AT (1) ATE512982T1 (xx)
AU (1) AU2002331244B2 (xx)
CA (1) CA2454756C (xx)
HK (1) HK1062444A1 (xx)
IL (1) IL160142A0 (xx)
WO (1) WO2003016522A2 (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (en) 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
US7354897B2 (en) * 2002-06-07 2008-04-08 Brigham & Women's Hospital, Inc. Method and composition for inhibiting or slowing blood coagulation
US7914792B2 (en) * 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
US7439221B2 (en) * 2003-10-17 2008-10-21 Emory University Methods and compositions for modulating gamete adhesion
AU2006243905B2 (en) * 2005-05-13 2011-09-01 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor VIII and sepsis
CN1322115C (zh) * 2005-07-06 2007-06-20 清华大学 载有外源配体分子的胞外体及其制备方法与应用
ES2880460T3 (es) * 2006-03-09 2021-11-24 Aethlon Medical Inc Eliminación extracorpórea de partículas microvesiculares
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
CA2697629A1 (en) 2007-09-24 2009-04-02 The University Of Queensland Molecular delivery vesicle
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CA2742324A1 (en) * 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
PT2419144T (pt) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
FR2950350B1 (fr) * 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
KR20130032646A (ko) * 2011-09-23 2013-04-02 삼성전자주식회사 막단백질 및 광발생 단백질이 결합된 융합단백질을 포함하는 재조합 엑소좀을 이용한 엑소좀 수득율을 측정하는 방법
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2014168721A2 (en) * 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
EP3335721A1 (en) 2013-04-12 2018-06-20 Evox Therapeutics Limited Therapeutic delivery vesicles
GB201313249D0 (en) * 2013-07-25 2013-09-11 Isis Innovation Method
EP3011008B1 (en) 2013-06-18 2020-06-24 Oxford University Innovation Limited Method of detecting the presence or absence of autoantibodies
EP2862874B1 (en) 2013-10-15 2018-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles
JP2016535009A (ja) * 2013-10-17 2016-11-10 チルドレンズ ホスピタル ロサンゼルス 抗体依存性エキソソーム治療の方法
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
CN105859837B (zh) * 2014-10-22 2020-11-20 台北医学大学 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用
US10702581B2 (en) * 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
US9840542B2 (en) 2015-09-11 2017-12-12 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
WO2017118764A1 (en) * 2016-01-07 2017-07-13 Thomas Brocker Novel approaches for the in vivo and in vitro visualization of dying cells
WO2017127827A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
AU2017226956A1 (en) 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
WO2017173367A2 (en) 2016-03-31 2017-10-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
US20190112351A1 (en) * 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Preparations containing protein-charged exosomes, methods for their production and uses thereof
US10487143B2 (en) * 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
CN108324735B (zh) * 2017-01-20 2024-02-09 李莉 用于疾病治疗的胞外体制剂及其应用
CN107185612B (zh) * 2017-03-17 2020-12-01 庶安永龄(厦门)健康产业有限公司 一种应用于外泌体捕获的微流体芯片及其制备方法
US11672849B2 (en) * 2017-05-10 2023-06-13 University Of Louisville Research Foundation, Inc. Method of inhibiting lung or breast cancer growth with engineered embryonic stem-cell derived exosomes compositions
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US11938219B2 (en) 2017-07-29 2024-03-26 University Of Southern California Synthetic extracellular vesicles for novel therapies
US11517530B2 (en) * 2017-09-27 2022-12-06 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic agents specifically delivered by exosomes for cancer treatment
EP3731849A4 (en) * 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
CN114173807B (zh) * 2019-09-02 2024-03-19 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
CN112824530A (zh) * 2019-11-20 2021-05-21 中国科学院深圳先进技术研究院 一种hek293f悬浮细胞高效电转染方法
US20210338822A1 (en) * 2020-01-22 2021-11-04 Agex Therapeutics, Inc. Therapeutic exosomes and method of producing them
KR20220139926A (ko) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 인공 시냅스
AU2022404756A1 (en) 2021-12-06 2024-06-20 Ciloa Chimeric adiponectin polypeptides, extracellular vesicle comprising the same, and uses thereof
CN116769717B (zh) * 2023-04-18 2024-06-11 河南中医药大学第一附属医院 一种靶向外泌体及其制备方法和应用
CN116676265B (zh) * 2023-04-18 2024-05-24 河南中医药大学第一附属医院 一种酸敏融合肽靶向外泌体及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455031A (en) 1990-11-01 1995-10-03 Cancer Research Fund Of Contra Costa Polypeptide with 46 Kdalton HMFG differentiation antigen binding specificity, composition, kit and diagnostic method
US5972337A (en) * 1990-11-01 1999-10-26 Cancer Research Fund Of Contra Costa 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
EP1004664A1 (en) * 1998-11-24 2000-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods using lactadherin or variants thereof
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
CA2431212A1 (en) 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
EP1417229B1 (en) 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
EP1483372A2 (en) 2002-03-14 2004-12-08 Anosys, Inc. Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions

Also Published As

Publication number Publication date
HK1062444A1 (en) 2004-11-05
EP1417229A2 (en) 2004-05-12
JP2005503791A (ja) 2005-02-10
CN1543476A (zh) 2004-11-03
WO2003016522A2 (en) 2003-02-27
EP1417229B1 (en) 2011-06-15
US20040197314A1 (en) 2004-10-07
US7704964B2 (en) 2010-04-27
CN100590131C (zh) 2010-02-17
CA2454756A1 (en) 2003-02-27
ATE512982T1 (de) 2011-07-15
AU2002331244B2 (en) 2007-02-15
CA2454756C (en) 2014-02-18
WO2003016522A3 (en) 2003-08-28
JP4662708B2 (ja) 2011-03-30

Similar Documents

Publication Publication Date Title
IL160142A0 (en) Methods and compounds for the targeting of protein to exosomes
MXPA02012106A (es) Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
AU6063500A (en) Glycoprotein vi and uses thereof
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
MXPA02010670A (es) Nuevas moleculas co-estimuladoras de celula dendritica.
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
NZ591415A (en) Haemophilus influenzae type B
DK0471011T4 (da) Humant lactoferrin-cDNA-sekvens
EP1487966A4 (en) SECRETION OF PROTEINS WITH MULTIPLE DISULFIDE BINDINGS IN BACTERIA AND USES THEREOF
WO1995019435A3 (en) T cell antigen receptor v region proteins and methods of preparation thereof
WO2001085782A3 (en) Fusion receptor from TNF family
AU1172202A (en) Far red shifted fluorescent proteins
WO1999019470A3 (en) Gfp-annexin fusion proteins
WO2002068459A3 (en) Non aggregating fluorescent proteins and methods for using the same
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
ATE295890T1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
WO2000012710A8 (en) Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO2002094992A3 (en) Directed evolution of protein in mammalian cells
GB0116460D0 (en) Biological products
AU6310100A (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin
EP1892251A3 (en) B7-related nucleic acids and polypeptides and their uses for immunomodulation
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
WO2001083552A3 (en) Human sez6 nucleic acids and polypeptides